[8] Parker, H. M., Johnson, N. A., Burdon, C. A., Cohn, J. S., O'Connor, H. T., & George, J. (2012). Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of hepatology, 56(3), 664-671.
[9] Scorletti, E., Bhatia, L., McCormick, K. G., & Clough, G. F. (2015). Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: A systematic review. Journal of hepatology, 62(1), 127-134.
[10] Dong, H., Wang, N., Zhao, L., & Lu, F. (2015). Berberine in the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis. Evidence-based complementary and alternative medicine, 2015.
[11] Lan, J., Zhao, Y., Dong, F., Yan, Z., Zheng, W., Fan, J., & Sun, G. (2015). Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology, 161, 69-81.
[12] Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A. J., Diehl, A. M., Bass, N. M., ... & American Association for the Study of Liver, D. (2010). Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine, 362(18), 1675-1685.
[13] Harrison, S. A., Torgerson, S., Hayashi, P., Ward, J., Schenker, S., & American Association for Study of Liver, D. (2003). Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. The American journal of gastroenterology, 98(11), 2485.